Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Dapagliflozin for Type 2 Diabetes
Recruiting3 awardsPhase 4
Orlando, Florida
This trial will test if dapagliflozin can reduce kidney size in patients with type 2 diabetes who have high levels of sugar in their urine.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.